Literature DB >> 27688562

Effects of Low Dose Vasopressin in Catecholamine Resistant Septic Shock.

R M Sharma1, R Setlur2, K Prabhakaran3, A Rai4.   

Abstract

BACKGROUND: Septic shock commonly leads to death in critically ill patients. Severe hypotension resistant to conventional catecholamine leads to multiorgan failure. We studied the effectiveness of low dose vasopressin in resistant septic shock.
METHODS: Thirty critically ill patients with catecholamine resistant hypotension were included in the study. After adequate fluid resuscitation, infusion of norepinephrine and dobutamine was started. If the patient remained hypotensive, vasopressin was infused at a fixed rate of 0.04 unit/minute for 24 hours. Haemodynamic parameters and mortality rates were recorded. RESULT: There was a significant improvement in systolic and mean arterial pressure within four hours of starting vasopressin. This improvement continued throughout the 24-hour period. In addition, it was possible to withdraw dopamine in all the patients and significantly reduce infusion rates of dobutamine and norepinephrine. No significant complication was noted.
CONCLUSION: Low dose vasopressin at the rate of 0.04 unit/minute is an effective vasopressor in adult patients with catecholamine resistant septic shock.

Entities:  

Keywords:  Septic shock; Severe sepsis; Vasopressin

Year:  2011        PMID: 27688562      PMCID: PMC5035250          DOI: 10.1016/S0377-1237(08)80003-2

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  16 in total

1.  Early goal-directed therapy in the treatment of severe sepsis and septic shock.

Authors:  E Rivers; B Nguyen; S Havstad; J Ressler; A Muzzin; B Knoblich; E Peterson; M Tomlanovich
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

2.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

3.  Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia.

Authors:  Roger Resar; Peter Pronovost; Carol Haraden; Terri Simmonds; Thomas Rainey; Thomas Nolan
Journal:  Jt Comm J Qual Patient Saf       Date:  2005-05

4.  Vasopressin pressor hypersensitivity in vasodilatory septic shock.

Authors:  D W Landry; H R Levin; E M Gallant; S Seo; D D'Alessandro; M C Oz; J A Oliver
Journal:  Crit Care Med       Date:  1997-08       Impact factor: 7.598

Review 5.  Physiology of vasopressin relevant to management of septic shock.

Authors:  C L Holmes; B M Patel; J A Russell; K R Walley
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

6.  The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis.

Authors:  M W Dünser; A J Mayr; H Ulmer; N Ritsch; H Knotzer; W Pajk; G Luckner; N J Mutz; W R Hasibeder
Journal:  Anesth Analg       Date:  2001-07       Impact factor: 5.108

Review 7.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

Authors:  Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay
Journal:  Intensive Care Med       Date:  2003-03-28       Impact factor: 17.440

8.  Low-dose vasopressin in the treatment of vasodilatory septic shock.

Authors:  M B Malay; R C Ashton; D W Landry; R N Townsend
Journal:  J Trauma       Date:  1999-10

9.  Skin necrosis after extravasation of low-dose vasopressin administered for septic shock.

Authors:  Jeremy M Kahn; John P Kress; Jesse B Hall
Journal:  Crit Care Med       Date:  2002-08       Impact factor: 7.598

Review 10.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Authors:  R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; Mitchell M Levy
Journal:  Crit Care Med       Date:  2004-03       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.